



News Release

FOR IMMEDIATE RELEASE

March 5, 2020

CONTACT: Suzanna Cisneros, suzanna.cisneros@ttuhsc.edu

(806) 743-7605

CPRIT Awards Research Grant to C. Patrick Reynolds *Funds to Aid Childhood, Adolescent Cancer Study*

The Cancer Prevention and Research Institute of Texas (CPRIT) in February announced a \$1,196,214 grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at the Texas Tech University Health Sciences Center (TTUHSC).

Neuroblastoma is the most common cancer outside of the brain in infants and young children and is challenging to treat, especially in patients that relapse after initial therapy. GD2 is a complex molecule highly expressed on neuroblastoma cells and is a target for successfully treating tumors. Dinutuximab, an antibody binding to GD2, can enhance chemoimmunotherapy both in patients and in preclinical models.

Neuroblastoma is the most common cancer outside of the brain in infants and young children and is challenging to treat, especially in patients that relapse after initial therapy. GD2 is a complex molecule highly expressed on neuroblastoma cells and is a target for successfully treating tumors.

This recent grant from CPRIT will enable us to understand how tumor cells escape therapy with an antibody that is effective